126.85USD-3.91%Mkt Cap: 6.11B USDP/E: —Last update: 2026-06-01
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolis…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap6.11B USD
Enterprise Value6.42B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-177.04M USD
Revenue/Share—
Last Price126.85 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees155
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)179.57
PEG—
EV/EBITDA-34.42
EV/Revenue—
P/S—
P/B120.04
EPS (TTM)-3.90
EPS (Forward)0.74
52W Range
10.5083% of range151.02
52W High151.02 USD
52W Low10.50 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-176.06%
ROA-37.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-153.28M USD
CapEx (TTM)249.00K USD
FCF Margin—
FCF Yield-1.82%
Net Debt-63.62M USD
Net Debt/EBITDA0.34
Balance Sheet
Debt/Equity3.20
Current Ratio12.31
Quick Ratio11.65
Book Value/Sh1.107 USD
Cash/Share7.937 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)169.00 USD
Target Range157.00 USD – 189.00 USD
# Analysts11
Ownership
Shares Out.48.77M
Float26.81M
Insiders10.01%
Institutions101.30%
Short Interest
Short Ratio8.0d
Short % Float29.45%
Short % Out.19.60%
Shares Short9.56M
Short (prev mo.)8.80M
Technical
SMA 50123.07 (+3.1%)
SMA 20094.14 (+34.7%)
Beta0.09
S&P 52W Chg27.94%
Avg Vol (30d)1.08M
Avg Vol (10d)971.08K
Technical Indicators
RSI (14)51.4
MACD3.0726
MACD Signal3.7716
MACD Hist.-0.6990
BB Upper146.21 USD
BB Middle133.95 USD
BB Lower121.69 USD
BB Width18.31%
ATR (14)8.369 USD
Vol Ratio (20d)0.72x